Emergency contraception: An underutilized resource

This emergency contraception update and telephone triage guide can help ensure that your patients get the help they need, when they need it.

PRACTICE RECOMMENDATIONS

- Offer emergency contraception (EC) to any woman who reports contraceptive failure or unprotected intercourse within the last 5 days; no clinical exam is necessary. (B)
- Prescribe a progestin-only EC or ulipristal acetate, both of which are more effective and have fewer adverse effects than an estrogen-progestin combination. (A)
- Consider giving sexually active teens <17 years an advance prescription for EC, as it is not available over the counter to this age group. (C)

Strength of recommendation (SOR)

- A: Good-quality patient-oriented evidence
- B: Inconsistent or limited-quality patient-oriented evidence
- C: Consensus, usual practice, opinion, disease-oriented evidence, case series

The average American woman will spend more than 30 years of her life trying to prevent pregnancy—not always successfully. Each year, half of the approximately 6 million pregnancies in the United States are unintended. Emergency contraception (EC) gives a woman a second chance to prevent pregnancy after a contraceptive failure or unprotected sex. But all too often, it isn’t offered and she doesn’t request it.

Lack of knowledge about EC continues to be a barrier to its use. Some women have heard about the “morning after pill,” but may not know that EC can be effective for up to 5 days after intercourse—or even that it’s available in this country. Others are unaware that it is possible to prevent pregnancy after intercourse, and mistakenly believe that EC drugs are abortifacients. In fact, they work primarily by interfering with ovulation and have not been found to prevent implantation or to disrupt an existing pregnancy.

Providers also contribute to the limited use of EC, often because they’re unfamiliar with the options or uncomfortable discussing them with patients, particularly sexually active teens.

This update can help you clear up misconceptions about EC with your patients. It also provides evidence-based information about the various types of EC, a review of issues affecting accessibility, and a telephone triage protocol to guide your response to women seeking postcoital contraception.

EC today: Plan B and beyond

Hormonal EC was first studied in the 1920s, when researchers found that estrogenic ovarian extracts interfered with pregnancy in animals. The first regimen was a high-dose estrogen-only formulation. In 1974, a combined estrogen-progestin replaced it. Known as the Yuzpe method for the physician who discovered it, this regimen used a widely available brand of combined estrogen-progestin oral con-
traceptive pills. The standard dose consisted of 100 mcg ethinyl estradiol (EE) and 0.5 mg levonorgestrel (LNG) taken 12 hours apart.²

Although the Yuzpe method is still in use, progestin-only EC—Plan B as well as generic (Next Choice) and single-dose (Plan B One-Step) LNG formulations—has become the standard of care because it has greater efficacy and fewer adverse effects.² There are 2 additional options: the copper intrauterine device (IUD), which is highly effective both as EC and as a long-term contraceptive,⁵ and ulipristal acetate (UPA), which received US Food and Drug Administration (FDA) approval in 2010. This second-generation anti-progestin, sold under the brand name Ella, is well tolerated and highly effective.⁸

EC efficacy: What the evidence shows

EC is most likely to work when used within 24 hours, but remains effective—albeit to varying degrees—for up to 120 hours (TABLE).²⁵⁻⁸⁻⁹ Thus, which EC is best for a particular patient depends, in part, on timing.

Copper IUDs have the highest success rate: Studies have found the copper IUD to be >99% effective in preventing pregnancy when inserted within 5 days of unprotected intercourse.⁵⁻¹⁰ The copper ions it contains have a toxic effect on sperm, and impair the potential for fertilization; the device may also make the endometrium inhospitable to implantation.⁵⁻¹⁰

A just-published systematic review of 42 studies in 6 countries over a period of more than 30 years yielded similar results: Among more than 7000 women who had the IUDs inserted after unprotected intercourse, the pregnancy rate was 0.09%.¹¹

But an IUD is appropriate only for women who want long-term contraception and would otherwise qualify for IUD insertion. By comparison, hormonal EC is not as effective and generally works best when used within a shorter time frame.

Progestin alone vs estrogen-progestin combo. To compare hormonal contraception, many researchers use a “prevented fraction”—an estimated percentage of pregnancies averted by treatment. A large World Health Organization-sponsored study found that the efficacy of progestin-only EC is superior to that of the estrogen-progestin combi-

nation, with prevented fractions of 85% and 57%, respectively. The progestin-only EC was also associated with significantly fewer adverse effects.¹²

In more recent studies, the prevented fraction for progestin-only EC has been found to range from 60% to 94%, while a meta-analysis of studies assessing estrogen-progestin EC revealed a prevented fraction of ≥74%.²

Although there is evidence suggesting that progestin-only EC may work for up to 5 days,¹³⁻¹⁴ it has FDA approval only for use within 72 hours of intercourse.¹³ A time-sensitive analysis showed that when it was used within 12 hours of intercourse, the pregnancy rate was 0.5%. The rate increased steadily to 4.1% when the progestin-based EC was taken 61 to 72 hours after intercourse, and rose by an additional 50% after an additional 12-hour delay.¹⁵

Hormonal EC is only effective before ovulation occurs. Once luteinizing hormone (LH) starts to rise, it is ineffective. However, the likelihood of pregnancy drops precipitously after ovulation, and there is no risk of pregnancy in the luteal phase, with or without EC.

One pill or 2? Both Plan B and the generic Next Choice are sold as 2-dose regimens, with one 0.75-mg tablet taken within 72 hours and the second taken 12 hours later. Plan B One-Step, which consists of a single 1.5-mg tablet, is clinically equivalent to the 2-dose formula,¹⁶ but is more convenient and may improve adherence. Notably, though, one large randomized controlled trial (RCT) in China found that the 2-pill regimen was significantly more effective in preventing pregnancy in women who had further acts of unprotected intercourse after treatment.¹⁷

UPA has a 5-day window. UPA has FDA approval for use within 120 hours of unprotected intercourse and has been found to be more effective than progestin-only EC, especially when used on Day 4 or 5 (72-120 hours).⁶ Adverse effects are mild to moderate, similar to those of LNG, and may include headache, abdominal pain, nausea, dysmenorrhea, fatigue, and dizziness.⁸

The medication binds to progesterone receptors, acting as an antagonist as well as a partial agonist. The mechanism of action depends on the phase of the woman’s cycle. Taken during the midfollicular phase, UPA
Ulipristal acetate (Ella) is more effective than progestin-only EC, especially when used between 72 and 120 hours after intercourse.

**TABLE**

Emergency contraception: Comparing methods*2,5,8,9

<table>
<thead>
<tr>
<th>EC method</th>
<th>Dose and timing</th>
<th>Benefits</th>
<th>Adverse effects/ drawbacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen-progesterin OCs</td>
<td>100 mcg EE and 0.5 mg LNG, taken 12 h apart; First dose within 72 h</td>
<td>Easily accessible and widely available; patient may use OCs she already has at home</td>
<td>Higher rates of adverse effects, including nausea, vomiting, headache; less effective than other methods</td>
</tr>
<tr>
<td>Progestin-only (Plan B, Next Choice, others)</td>
<td>1.5 mg LNG within 72 h (available in divided doses or in a single tablet; 2 tablets may be taken as a single dose)</td>
<td>Available OTC for patients ≥17 y; more effective and fewer adverse effects than estrogen-progesterin</td>
<td>Prescription required for patients &lt;17 y; Approved for use within 72 h; effectiveness diminishes thereafter</td>
</tr>
<tr>
<td>UPA (Ella)</td>
<td>30 mg UPA, taken ≤120 h</td>
<td>More effective than LNG; fewer adverse effects than estrogen-progesterin Efficacy remains high ≤5 days</td>
<td>Prescription required; not available at all pharmacies Not studied in breastfeeding*</td>
</tr>
<tr>
<td>Copper IUD</td>
<td>Insert ≤120 h</td>
<td>Extremely effective Provides immediate, long-term contraception</td>
<td>Insertion requires staff training; higher cost than oral EC</td>
</tr>
</tbody>
</table>

EC, emergency contraception; EE, ethinyl estradiol; IUD, intrauterine device; LNG, levonorgestrel; OCs, oral contraceptives; OTC, over the counter; UPA, ulipristal acetate.

*Low doses of mifepristone (<25-50 mg)—approved as an abortifacient in much larger doses—may also be used as EC.

†Dosage should be repeated if vomiting occurs within 3 hours.

‡Advise patients to avoid breastfeeding for 36 hours.

inhibits follicle development. In the advanced follicular phase, just prior to ovulation, it delays LH peak and postpones ovulation.

In one small study in which women were randomized to either UPA or placebo, researchers found that the drug delayed ovulation for ≥5 days in about 60% of those who took it; in comparison, ovulation occurred by Day 5 in every woman in the placebo group.

How accessible is EC?

EC has a tumultuous history in the United States, and accessibility depends on a variety of factors—age among them.

Plan B, for instance, is subject to a 2-tier system. It was approved in 1999 as a prescription-only product and has been available over the counter (OTC) to women 17 years and older since 2009. Younger women can get it only by prescription.

Nonetheless, Plan B made the news again last year, when US Health and Human Services Secretary Kathleen Sebelius overruled an FDA decision to give teens younger than 17 OTC access. Thus, the age restriction remains in place, although there is no medi-
FIGURE

Telephone triage protocol for emergency contraception

1. Patient calls to report unprotected sex/contraceptive failure and/or request EC.

   Q: Was unprotected sex <5 days (120 h) ago?
   - Yes: Schedule immediate visit for pregnancy test & possible EC.
   - No: Proceed to next question.

   Q: Was her last period within the last 30 d?
   - Yes: Review EC options with patient.
   - No: Recommend pregnancy test.

2. Review EC options with patient:

   Plan B/Next Choice (LNG)
   - Provide Rx for EC if needed.
   - Counsel patient; consider advance Rx.

   Ella (UPA)

   Copper IUD
   - Schedule clinic visit within 5 days.

EC, emergency contraception; IUD, intrauterine device; LNG, levonorgestrel; Rx, prescription; UPA, ulipristal acetate.
Adapted from: Reproductive Health Access Project. http://www.reproductiveaccess.org/contraception/tel_triage_ec.htm.4

Offer EC to any woman who reports a contraceptive failure or unprotected intercourse, regardless of the phase of her menstrual cycle.

Accessibility of EC also may vary from one part of the country to another. Some states have enacted laws with conscience clauses that allow pharmacists to refuse to dispense EC. Others have worked to increase access by authorizing pharmacists to initiate and dispense EC on their own, provided they have written protocols.
Because EC may delay ovulation, advise patients to use an alternative method of contraception for the duration of their cycle.

Because EC may delay ovulation, advise patients to use an alternative method of contraception for the duration of their cycle.

Because EC may delay ovulation, advise patients to use an alternative method of contraception for the duration of their cycle.
References


The National Allergy Survey Assessing Limitations (NASAL): Patient and Health Care Professional Perspectives in Allergic Rhinitis

This supplement presents results from the National Allergy Survey Assessing Limitations (NASAL), which provides an up-to-date assessment of symptoms, burden of disease, and patient and provider perspectives concerning allergic rhinitis and nasal allergy treatment in the United States.

The survey was conducted by Strategic Pharma Solutions, LLC, in conjunction with the national public research organization, Abt SRIRI, with funding provided by Teva Respiratory, LLC.